Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Pressure On Pharma: UN Report Backs Compulsory Licensing

Executive Summary

Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.

Advertisement

Related Content

Patent Prognosis: Pfizer’s Chief IP Counsel On The Year Ahead
India's Proposed Tweak Of New Drug Rules: Bridge To Data Exclusivity?
Will UN Report On Access To Medicines Change Anything?
WHO's New Hepatitis C Drug Patent Profiles To Boost Access Worldwide
India Compulsory Licensing: What USTR Hearing Transcripts Say
GSK Is First To Share Cancer Drug Patents With Poor Countries
UN Panel To Hear Stakeholder Ideas On IP, Innovation And Access
PhRMA keeps eye on Indian compulsory licensing activity
Cut price generics in sight as Gilead licenses Sovaldi
Unlikely allies MSD, Cipla link to co-market Isentress in India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel